Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX’s U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight’s regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPure™ HT decellularized human tendon in the U.S. in early 2018, for an initial application in anterior cruciate ligament repair.
Jesus Hernandez, CellRight’s Chief Executive Officer, will join Tissue Regenix as Chief Scientific Officer.
Sources: Tissue Regenix Group plc; ORTHOWORLD Inc.
Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX's U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight's regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPureâ„¢...
Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.
The transaction more than doubles TRX’s U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight’s regenerative osteoconductive bone scaffolds.
TRX plans to launch its OrthoPure™ HT decellularized human tendon in the U.S. in early 2018, for an initial application in anterior cruciate ligament repair.
Jesus Hernandez, CellRight’s Chief Executive Officer, will join Tissue Regenix as Chief Scientific Officer.
Sources: Tissue Regenix Group plc; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.